Regeneron COVID-19 antibody drug reduces infection risk 82% in clinical trial

Regeneron said Nov. 8 that its COVID-19 antibody cocktail reduced the risk of contracting COVID-19 by 81.6 percent for eight months after administration in a phase 3 clinical trial.

During the eight-month follow-up period, Regeneron said there were no hospitalizations from COVID-19 infection among the people receiving the antibody cocktail, called REGEN-COV, and six in the placebo group.